Glioblastoma is one of the most malignant tumors, after decades of research, the treatment of glioblastoma patients is still limited to traditional surgery, radiation and chemotherapy, and the survival of glioblastoma patients is still only a few months. Our previous research has shown that gliomas likely originate from adult neural stem cells with the ability to self-renew. In gliomas that have already formed, there is a subset of tumor cells that express stem cell markers that are critical for cell resistance to chemotherapy and tumor recurrence. At present, on the one hand, we study the functions of key drivers in the process of tumor occurrence and maintenance through mouse genetics, primary tumor cells and other systems; on the other hand, we explore the relationship between brain tumors and the unique immune microenvironment of the brain, and explore the use of small molecule inhibitors, CAR-T, oncolytic virus and other means to intervene in tumor.

Current research directions in the laboratory include:

1.Investigating the impact of neutrophils in the glioblastoma immune microenvironment on tumor initiation and progression.

2.Exploring the differences in the immune microenvironment between central and subcutaneous tumors and studying CART (Chimeric Antigen Receptor T-cell) targeted therapy for glioblastoma.

3.Studying the correlation between glioblastoma stem cell subtypes and drug sensitivity.

4.Investigating the process of glioblastoma initiation and development through the induction of spontaneous tumor formation in mice, combining pathological staining and transcriptome sequencing techniques.

5.Identifying small molecules and drug targets that effectively intervene in the MES (Mesenchymal) subtype of glioblastoma and elucidating their mechanisms of action.

6.Establishing methodologies combining Drug-seq and CRISPR Screening to describe the transcriptional characteristics of small molecules and integrating them with phenotypes to elucidate intracellular gene regulatory networks.

7.Establishing, identifying, and utilizing an immunogenic mouse glioblastoma model.